The publication of the first series focuses on gene therapy and haemophilia from both patient and expert points of view. The five-part series has been created to help patients and the general public understand and demystify some of the concepts related to gene therapy in haemophilia.

This series is the first major piece of patient-focused discussion and education about gene therapy and haemophilia.

What is gene therapy? with Prof. Flora Peyvandi

An overview in gene therapy for haemophilia A and B with Dr. Paul Giangrande

How does a clinical trial in gene therapy for haemophilia work? with Dr. Dan Hart

Safety and gene therapy with Prof. Michael Makris

Gene therapy: A patient’s perspective with Jack Grehan

What is gene therapy? with Prof. Flora Peyvandi. Flora Peyvandi is the Director of the Haemophilia and Thrombosis Centre Angelo Bianchi Bonomi,  Fondazione IRCSS Ca’ Granda Ospedale Maggiore Policlinico in Milan, Italy and Chair of the EHC Medical and Advisory Group (MAG).

An overview in gene therapy for haemopphilia A and B with Dr. Paul Giangrande. Paul Giangrande is the former Head of the Oxford Haemophilia Centre in the United Kingdom where he served as a consultant haematologist. From 2013 to 2018 he was the Chair of the EHC Medical Advisory Group (MAG).

How does a clinical trial in gene therapy for haemophilia work? with Dr. Dan Hart. Dan Hart is Honorary Consultant Haematologist at The Royal London Hospital Centre, Barts Health NHS Trust in London, United Kingdom. He is also a member of the EHC Medical and Scientific Advisory Group (MASAG).

Safety and gene therapy with Prof. Michael Makris. Michael Makris is the Director of the Sheffield Haemophilia and Thrombosis Centre in Sheffield, United Kingdom. He is a member of the EHC Medical Advisory Group (MAG).

Gene therapy: A patient’s perspective with Jack Grehan.